US says breast cancer drug did not extend lives WASHINGTON – Follow-up studies of a Roche breast cancer drug showed that it failed to extend the lives of patients, federal health scientists said, opening the door for it to be potentially withdrawn for use in treating that disease. Read more on The Kentucky Post
Bristol drug extends survival in deadly skin cancer NEW YORK/CHICAGO (Reuters) – Bristol-Myers Squibb Co’s experimental skin cancer drug ipilimumab added an average of four months to the lives of patients with advanced melanoma, U.S. researchers said on Saturday, representing a major advance in a disease littered with drug failures. Read more on Reuters
A Phase I clinical trial of SNS-032, one of the first in a new class of drugs that inhibit cyclin-dependent kinases, demonstrated the drug’s safety and potential clinical action against advanced chronic lymphocytic leukemia (CLL). Source: General Cancer News Articles Provided by Cancer Compass
Compugen Ltd. announced the discovery and initial experimental validation of CGEN-928 as a drug target for the treatment of multiple myeloma. In recently completed studies, CGEN- 928, a membrane protein which previously had no known function or potential clinical utility, demonstrated broad expression in human multiple myeloma tumor cells, [...]
Lung cancer patients whose tumors over-express a cell surface molecule called CXCR4 do significantly worse than those who do not, Canadian researchers have found. Their work, reported at the 2nd European Lung Cancer Conference in Geneva, highlights the exciting possibility that the molecule could soon become a new [...]
Swedish pharma major AstraZeneca announced last Saturday new trial data showing that treatment with its cancer drug Iressa leads to improved life quality and fewer symptoms in patients with non- small cell lung cancer with EGFR mutation compared with chemotherapy. Source: General Cancer News Articles Provided by Cancer Compass
A common osteoporosis drug, raloxifene, reduces breast cancer risk by 38% in women at high risk for the disease, without causing the serious side effects of similar drugs, a new study shows. That suggests more high-risk women should consider taking raloxifene, also known as Evista, says Victor Vogel, main [...]
Roche to Seek Early Approval of Breast Cancer Drug (Update2) April 15 (Bloomberg) — Roche Holding AG will ask U.S. health regulators this year to approve the T-DM1 experimental breast cancer treatment, a medicine the company says may generate more than 2 billion Swiss francs ($1.89 billion) in annual sales. Read more on Bloomberg
Having a bad reaction to penicillin as a child doesn’t guarantee you’re still allergic decades later. And if the oncologist says you have to switch chemotherapies because of an allergic reaction, well, maybe not. Source: General Cancer News Articles Provided by Cancer Compass
A drug already prescribed to shrink benign, enlarged prostates has been shown to reduce the risk of a prostate cancer diagnosis by 23 percent in men with an increased risk of the disease, a large international trial has found. Results are reported April 1 in the New England Journal of [...]